According to the associated press, gunshots rang out near the government building in Kiev, Ukraine.

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Chinese tech giant Huawei and Vietnam’s SHB Bank enter strategic partnership to accelerate penetration into SE Asia's financial cloud market

On April 22, Saigon-Hanoi Commercial Joint Stock Bank (SHB) of Vietnam officially announced the signing of a strategic cooperation agreement with Chinese tech giant Huawei. Under the agreement, Huawei will be deeply involved in SHB’s technical architecture design, assisting in the construction of its core data platform and providing comprehensive operational stability and security assurance.

Chinese digital payment WeChat Pay integrates national QR codes in five Asian countries, entering a unified era of "scan-and-pay" cross-border payments

On April 21, the official WeChat Pay account announced that the national QR code payment systems of South Korea, Sri Lanka, Thailand, Malaysia, and Singapore have officially integrated with WeChat Pay. This development means that Chinese tourists visiting these countries no longer need to download local apps or manually exchange currency.

Chinese technology enterprise Dreame (追觅科技) reports eight consecutive years of doubled revenue, leading market share in over 30 countries

On April 20, Yu Hao (俞浩), founder and CEO of Dreame Technology (追觅科技), shared his unique business philosophy in an interview. He revealed that since its founding in 2017, Dreame has achieved an average annual revenue growth of 100% for eight consecutive years. By the end of 2025, Dreame’s products reached 120 countries and regions, securing the No. 1 market share in the robotic vacuum segment across more than 30 countries, including Germany, Italy, and Singapore.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.